Powell B L, Craig J B
Am J Med Sci. 1987 Jul;294(1):33-41. doi: 10.1097/00000441-198707000-00005.
Adjuvant chemotherapy for microscopic disease following eradication of clinically detectable lesions by primary surgery and/or radiotherapy is of documented benefit for some oncology patients. However, for many primary cancers efficacy is limited to specific subgroups of patients or has demonstrated no advantage over primary therapy alone. The rationale for adjuvant chemotherapy and results of selected trials are reviewed. In patients for whom adjuvant therapy is of demonstrated benefit, further trials aimed at delineation of patient selection factors, optimal chemotherapy regimens and schedules, and duration of therapy are needed; progress in adjuvant treatment of other subgroups may require development of more effective antineoplastic drugs, in addition to exploration of these factors.
对于一些肿瘤患者，在通过初次手术和/或放疗根除临床可检测病变后，针对微小病灶进行辅助化疗已被证明是有益的。然而，对于许多原发性癌症，其疗效仅限于特定的患者亚组，或者并未显示出比单纯的初次治疗更具优势。本文综述了辅助化疗的基本原理及部分试验结果。对于已证明辅助治疗有益的患者，需要进一步开展试验，以明确患者选择因素、最佳化疗方案和疗程，以及治疗持续时间；对于其他亚组患者，辅助治疗取得进展可能不仅需要探索这些因素，还需要研发更有效的抗肿瘤药物。
